Zyprexa 10 mg (Olanzapine)

Adult dose

The therapeutic dose of this medicine should be adjusted according to the patient's clinical condition. Dose increases beyond the general recommended daily dose of 10 mg are recommended only after an appropriate clinical evaluation. 1. Adults 1) Schizophrenia (1) The recommended initial dose is 5∼10 mg of olanzapine once daily. (2) Maintenance treatment: There is no definitive answer as to how long treatment with this medicine should continue. Its efficacy was demonstrated in a placebo-controlled study in patients with schizophrenia whose symptoms had stabilized after approximately 8 weeks of treatment with this medicine and who received maintenance treatment with doses of 10∼20 mg daily for 8 months. The need for maintenance treatment at an appropriate dose should be evaluated periodically. 2) Bipolar disorder (1) Treatment of manic or mixed episodes associated with bipolar I disorder The initial dose is 15 mg of this medicine once daily as monotherapy, or 10 mg once daily as adjunctive therapy with lithium or valproate. (2) Prevention of recurrence in bipolar disorder The recommended initial dose is 10 mg once daily. Patients who have received this medicine for treatment of mania should continue taking the same dose to prevent recurrence. If a new manic, mixed, or depressive episode occurs, treatment with this medicine should continue, together with adjunctive therapy to treat mood symptoms as clinically indicated (with the necessary dose optimized). 3) For schizophrenia; treatment of manic and mixed episodes associated with bipolar I disorder; and prevention of recurrence in bipolar disorder, the daily dose may be adjusted within the range of 5 mg to 20 mg based on clinical status. Dose increases above the recommended initial dose are recommended only after an appropriate clinical evaluation and should generally be made at intervals of at least 24 hours. If treatment with this medicine is discontinued, the dose should be tapered gradually and cautiously. 4) Acute treatment of depressive episodes associated with bipolar I disorder Initiate treatment with 5mg of olanzapine once daily, then increase to 10mg once daily. Administer this medicine at bedtime and adjust the dose as appropriate according to age and symptoms, but do not exceed 20mg daily. Food does not affect drug absorption; therefore, this medicine may be taken with or without food. 2. Administration in specific populations 1) Older adults Starting at a dose of 5 mg or less daily may be considered when there is sufficient clinical justification. 2) Patients with renal or hepatic impairment Consider a low initial dose (5 mg). In moderate hepatic impairment (cirrhosis, Child-Pugh Class A or B), the initial dose is 5 mg and should be increased cautiously. 3) Patients with multiple factors that delay the metabolism of this medicine (female sex, older age, and nonsmoking status) may also be started at a low dose.

This medication can lead to serious side effects such as neuroleptic malignant syndrome, so if symptoms such as high fever, muscle rigidity, or changes in mental state occur, discontinue use immediately and consult a healthcare professional. It is not recommended for the treatment of psychosis or behavioral disorders related to dementia, as there may be an increased risk of mortality and cerebrovascular disease in dementia patients taking this medication. Prolonged use may lead to tardive dyskinesia, so if abnormal symptoms occur, dosage adjustment or cessation should be considered. It may take several days to weeks for the effects of this medication to be noticed, hence it is important to monitor the patient's condition closely during the early stages of treatment. It can affect blood sugar control, so diabetic patients or those at risk should regularly monitor blood glucose and weight, and report any symptoms of hyperglycemia to a healthcare professional. It may cause changes in lipid levels, requiring regular testing for patients with dyslipidemia. Sudden discontinuation of this medication can lead to withdrawal symptoms such as sweating, insomnia, and anxiety, so it is advisable to taper off gradually. It is not recommended for patients with Parkinson's disease due to the risk of symptom exacerbation. Patients with heart diseases may have an increased risk of acute cardiac events and should be monitored regularly for cardiovascular status. Patients with hypersensitivity to this medication, angle-closure glaucoma, those receiving epinephrine, or lactose intolerant individuals should not be administered this drug. Close monitoring and management are necessary for patients with liver dysfunction, history of seizures, cardiovascular diseases, elderly patients, diabetic patients, pregnant and breastfeeding women. This medication may cause drowsiness and dizziness, so caution is necessary when driving or operating machinery. Regular check-ups such as blood tests and liver function tests are recommended during treatment, and any abnormal symptoms should be reported to a healthcare professional immediately. In case of overdose, since there is no specific antidote, seek immediate medical attention.

• High fever
• muscle rigidity
• changes in mental state
• irregular heartbeat
• changes in blood pressure
• tachycardia
• sweating
• cardiac arrhythmia
• elevated creatine phosphokinase
• myoglobinuria

This medication should be stored in a tightly sealed container to prevent air from entering and kept at room temperature between 15 and 30 degrees Celsius. This will help maintain the effectiveness of the medication and prevent deterioration.

Appearance

White or pale gray round film-coated tablet

Package unit

Domestic use: 28 tablets (7 tablets/PTP × 4), 100 tablets/bottle; Export: 28 tablets (7 tablets/PTP × 4), 56 tablets (7 tablets/PTP × 8)